FY2029 Earnings Estimate for TCRX Issued By HC Wainwright

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of TScan Therapeutics in a report issued on Thursday, March 6th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of $0.44 for the year. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The business had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

Several other research analysts have also issued reports on TCRX. Barclays decreased their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC cut their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and an average price target of $9.20.

TScan Therapeutics Price Performance

NASDAQ TCRX opened at $1.98 on Friday. The company’s 50 day simple moving average is $2.43 and its 200 day simple moving average is $4.04. The firm has a market capitalization of $105.67 million, a PE ratio of -1.87 and a beta of 0.91. TScan Therapeutics has a 12 month low of $1.82 and a 12 month high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently bought and sold shares of the stock. Heck Capital Advisors LLC acquired a new stake in TScan Therapeutics in the 4th quarter worth approximately $61,000. Woodline Partners LP increased its stake in shares of TScan Therapeutics by 6.7% in the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock worth $352,000 after purchasing an additional 7,282 shares during the period. Squarepoint Ops LLC bought a new position in TScan Therapeutics in the 4th quarter worth approximately $59,000. Tang Capital Management LLC bought a new position in TScan Therapeutics during the fourth quarter worth $358,000. Finally, Shay Capital LLC acquired a new position in TScan Therapeutics during the 4th quarter valued at $65,000. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.